(2)
Here’s why I think they’re about to make a splash:
A Strong and Diverse Pipeline
InMed is pioneering treatments using proprietary small molecule drug candidates that target the CB1/CB2 receptors. Their three key programs are focused on: (1)(6)
🔬 Alzheimer’s Disease
🔬 Ocular Diseases (like Age-related Macular Degeneration)
🔬 Dermatology (focused on EB and potential for severe chronic itch conditions)
Breaking New Ground in Alzheimer’s
One of their most promising preclinical candidates, INM-901, offers a unique and differentiated approach to treating Alzheimer’s. Unlike current therapies,
INM-901 doesn’t just slow down cognitive decline—it shows the potential to restore brain function. Here’s why it’s so innovative:: (1)(6)
🧠 Targets multiple biological pathways in Alzheimer’s, offering a more comprehensive approach than current treatments.
🧠 Crosses the blood-brain barrier safely and effectively—this is something that most treatments struggle to do.
🧠 Demonstrates improvements in
cognitive function, memory, and anxiety-related behavior in preclinical studies.
🧠 Supports neuronal health by reducing inflammation and protecting brain cells from damage.
With a Fierce Biotech webinar coming up and the backing of industry leaders, it’s clear this Alzheimer’s program is gaining serious momentum. (5)
Dermatology Phase 2 Completed–
INM-755
InMed also recently completed a successful Phase 2 trial for INM-755, a cream developed to treat Epidermolysis bullosa (EB),and can potentially be developed for severe itch conditions. Highlights include: (1)(6)
🌿 Positive anti-itch results and a favorable safety profile.
🌿 Potential for broad indications with large market potential.
🌿 Pursuing partnerships
to advance this promising treatment.
Revenue-Generating Subsidiary: BayMedica
InMed isn’t just an R&D story—they’re already generating revenue through BayMedica, their wholly-owned subsidiary that focuses on rare cannabinoids. BayMedica: (1)(6)
🦠Generated ~$5M in annual sales, making InMed one of the rare biotech companies that’s already generating
revenue!
🦠Sells high-purity, bioidentical rare cannabinoids used in the health and wellness market.
Strong Financial Position
💼 13.4M shares outstanding and a market cap of ~$4.0M.
💼 Balance sheet stronger than their market cap, with approximately $6M in cash (as of June 30th 2024)
💼 Consistently strong trading volume on news, showing interest is high.
With multiple programs in areas of
high unmet needs, a growing revenue stream, and with increased M&A activity in the Alzheimer’s space , InMed (INM) is well positioned for growth. (1)(6)
Check Out InMed Pharmaceuticals (INM) Now!
This is a unique pharma company that’s pushing boundaries in both drug development and revenue generation. With Alzheimer’s research heating up and a robust
pipeline, InMed (Nasdaq: INM) is one to watch closely.
Don’t miss out—take a closer look at this innovative company NOW!
To your success,
Max Masters
Co-founder, Market Tips Newsletter
Sources:
1. https://bit.ly/3A26zNN
2. https://bit.ly/40ffFBd
3. https://bit.ly/3Ca2ebG
4. https://yhoo.it/4eZ4ocU
5. https://bit.ly/3BYUnxJ
6. https://yhoo.it/3Ye8HKe
